Verastem Inc (VSTM) Q4 2025 Earnings Call Transcript

Why It Matters

The early commercial traction and strong clinical signals for COPIKTRA position Verastem to capture a niche in relapsed CLL, SLL and FL, while its expanded financing supports continued pipeline development.

Key Takeaways

• COPIKTRA Q1 revenue $1.7M, up 38% QoQ.
• 92% of targeted health plans reimburse COPIKTRA.
• Phase 3 DUO shows 16.4‑month PFS vs 9.1 months.
• 2019 product revenue guidance $10‑12M.
• Cash $212M; borrowing limit increased to $75M.

Pulse Analysis

Verastem’s duvelisib, marketed as COPIKTRA, is the first oral dual PI3K‑delta/gamma inhibitor approved in the United States, targeting relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular lymphoma. The Q1 2019 earnings call revealed that the product’s modest $1.7 million revenue is already growing at a 38% quarter‑over‑quarter rate, underscoring early physician adoption despite the competitive landscape of BTK and BCL‑2 inhibitors. Achieving reimbursement from over 92% of targeted health plans has been pivotal, as payer coverage often dictates market penetration for specialty oncology therapies.

Beyond commercial metrics, Verastem highlighted robust clinical progress. The Phase 3 DUO trial demonstrated a median progression‑free survival of 16.4 months compared with 9.1 months for ofatumumab, reinforcing duvelisib’s efficacy advantage. Long‑term safety data from extended DUO and DYNAMO studies showed consistent adverse‑event profiles, while the company announced upcoming investigations, including the PRIMO Phase 2 study in peripheral T‑cell lymphoma and a venetoclax combination trial in CLL/SLL. A confirmatory Phase 3 study aimed at converting the accelerated follicular lymphoma approval into full approval is slated to begin later this year, further expanding the drug’s label.

Financially, Verastem entered the quarter with $211.7 million in cash and investments, bolstered by a revised loan agreement that lifted its borrowing limit to $75 million and reduced interest costs. Although the company posted a $38.1 million net loss, it provided 2019 product‑revenue guidance of $10‑12 million, reflecting confidence in the launch trajectory. The announced departure of Chief Commercial Officer Joe Lobacki introduces a leadership transition, but the board’s interim oversight and ongoing commercial infrastructure suggest continuity. Together, the commercial momentum, compelling clinical data, and strengthened balance sheet position Verastem for potential growth in a high‑unmet‑need oncology market.